What Is GLP-1? How GLP-1 Medications Work for Weight Loss

GLP-1: The Hormone Your Gut Produces After Every Meal

Glucagon-like peptide-1 is a 30-amino-acid peptide hormone secreted by intestinal L-cells, primarily in the ileum and colon, within 10 to 15 minutes of food entering the digestive tract. It belongs to the incretin family of hormones, which account for up to 70% of postprandial insulin secretion in healthy individuals [1]. GLP-1 was first characterized in the 1980s by researchers studying proglucagon processing.

The hormone works through three simultaneous pathways. First, it binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin release. This means insulin secretion ramps up only when blood sugar is elevated, reducing hypoglycemia risk. Second, GLP-1 suppresses glucagon secretion from alpha cells, lowering hepatic glucose output [2]. Third, and most relevant for weight management, GLP-1 activates receptors in the hypothalamus and brainstem that regulate appetite and satiety.

Native GLP-1 has a critical limitation. The enzyme dipeptidyl peptidase-4 (DPP-4) degrades it within roughly 2 minutes of secretion, giving it an extremely short plasma half-life [3]. This rapid breakdown is why the natural hormone alone cannot produce the sustained appetite suppression needed for meaningful weight loss. GLP-1 receptor agonist medications were engineered specifically to resist DPP-4 degradation, extending their activity from minutes to days or even weeks.

How GLP-1 Receptor Agonist Medications Produce Weight Loss

GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides designed to bind the same receptors as native GLP-1 but persist in the bloodstream far longer. Semaglutide, for example, has an albumin-binding fatty acid chain that extends its half-life to approximately 7 days, allowing once-weekly dosing [4]. This prolonged receptor activation produces weight loss through three well-documented mechanisms that work simultaneously.

Appetite reduction through central nervous system signaling. GLP-1 RAs cross the blood-brain barrier and activate receptors in the arcuate nucleus of the hypothalamus, the area postrema, and the nucleus tractus solitarius. These brain regions control hunger, reward-based eating, and satiety. Functional MRI studies show that semaglutide reduces neural responses to food cues in reward centers, decreasing cravings and the desire to eat between meals [5].

Delayed gastric emptying. GLP-1 RAs slow the rate at which food leaves the stomach by 20% to 40%. Patients feel full sooner during meals and stay full longer afterward [6]. This effect is most pronounced during early treatment and may partially attenuate over months, though appetite suppression from central pathways persists.

Reduced caloric intake. The combined effect of lower hunger and prolonged fullness translates to a measurable reduction in food consumption. In a controlled feeding study published in Nature Medicine, participants on semaglutide 2.4 mg ate approximately 24% fewer calories (roughly 500 fewer kcal per day) without being instructed to restrict their diet [7].

The weight loss is not instantaneous. Most patients notice appetite changes within the first 2 to 4 weeks of dose escalation, with weight loss accelerating during months 2 through 6 and typically plateauing between months 12 and 16.

FDA-Approved GLP-1 Medications for Weight Management

Three medications with GLP-1 receptor activity currently hold FDA approval specifically for chronic weight management. Each has a distinct dosing schedule, efficacy profile, and side effect pattern.

Liraglutide 3.0 mg (Saxenda). Approved in 2014, liraglutide was the first GLP-1 RA indicated for obesity. It requires daily subcutaneous injection. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3.0 mg produced 8.0% mean weight loss versus 2.6% with placebo at 56 weeks [8]. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states: "Liraglutide 3.0 mg is recommended as an option for chronic weight management in patients with a BMI of 30 kg/m² or greater" [9].

Semaglutide 2.4 mg (Wegovy). Approved in June 2021, semaglutide is administered once weekly. It demonstrated substantially greater efficacy than liraglutide. In STEP 1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [10]. One-third of participants lost 20% or more of their body weight. This was the first anti-obesity medication to approach the weight loss percentages previously seen only with bariatric surgery.

Tirzepatide (Zepbound). Approved for weight management in November 2023, tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. In SURMOUNT-1 (N=2,539), the 15 mg dose produced 22.5% mean weight loss at 72 weeks. Even the lowest 5 mg dose achieved 15.0% weight loss [11]. The dual-agonist approach appears to produce additive metabolic effects beyond GLP-1 receptor activation alone.

Other GLP-1 RAs (exenatide, dulaglutide, oral semaglutide 14 mg for diabetes) are FDA-approved for type 2 diabetes and may produce modest weight loss as a secondary benefit, but they do not carry an obesity indication at their current approved doses.

Clinical Trial Evidence: What the Data Actually Show

The evidence base for GLP-1 medications in weight loss now includes multiple large, randomized, placebo-controlled trials spanning thousands of patients and follow-up periods exceeding one year. The results are consistent across demographics, baseline BMI ranges, and the presence or absence of type 2 diabetes.

The STEP program for semaglutide 2.4 mg includes six phase 3 trials. STEP 1 enrolled adults without diabetes and showed 14.9% mean weight loss at 68 weeks [10]. STEP 2 (N=1,210) focused on adults with type 2 diabetes; semaglutide produced 9.6% weight loss versus 3.4% with placebo, a smaller but still clinically significant result reflecting the known difficulty of weight loss in this population [12]. STEP 3 added intensive behavioral therapy to the medication, yielding 16.0% weight loss, suggesting that lifestyle intervention amplifies drug efficacy. STEP 5 (N=304) extended follow-up to 104 weeks and confirmed that weight loss was maintained at 15.2% as long as the medication continued [13].

For tirzepatide, the SURMOUNT trials produced even larger treatment effects. SURMOUNT-2 (N=938) enrolled adults with obesity and type 2 diabetes; the 15 mg dose produced 14.7% weight loss at 72 weeks [14]. SURMOUNT-3 examined tirzepatide after a 12-week intensive lifestyle lead-in and showed an additional 18.4% body weight reduction beyond what participants had already lost through diet and exercise alone.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, described these results in The Lancet: "We are now entering an era where pharmacotherapy can produce weight reductions of 20% or more, fundamentally changing how we treat obesity as a chronic disease" [15].

Beyond weight, these medications improve metabolic parameters. Semaglutide 2.4 mg reduced waist circumference by an average of 13.5 cm in STEP 1. Systolic blood pressure fell by 6.2 mmHg. Triglycerides dropped by 18%, and C-reactive protein (a marker of systemic inflammation) decreased by 55% [10].

Cardiovascular and Cardiometabolic Benefits

GLP-1 medications do more than reduce body weight. The SELECT trial (N=17,604), published in The New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) by 20% in adults with established cardiovascular disease and overweight or obesity but without diabetes [16]. This was the first time any anti-obesity medication demonstrated a reduction in cardiovascular events.

The cardiovascular protection appeared early. Event curves began separating within the first year of treatment. The benefit was consistent regardless of baseline BMI, age, sex, or geographic region. Based on these data, the American Heart Association published a scientific statement in 2024 recognizing GLP-1 RAs as a treatment option for cardiovascular risk reduction in patients with obesity [17].

Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, is ongoing with results expected in 2027. Preliminary cardiometabolic data from SURMOUNT-1 showed improvements in blood pressure, lipid profiles, and inflammatory markers that parallel or exceed those seen with semaglutide [11].

GLP-1 RAs also show benefit in related conditions. The FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg slowed the progression of chronic kidney disease in patients with type 2 diabetes by 24% versus placebo, reducing the composite endpoint of kidney failure, sustained eGFR decline, and renal or cardiovascular death [18].

Who Is Eligible for GLP-1 Weight Loss Medications

FDA labeling for Wegovy and Zepbound specifies the following eligibility criteria: adults with a body mass index (BMI) of 30 kg/m² or greater, or adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea [10][11].

Wegovy also received FDA approval in December 2022 for adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex. The STEP TEENS trial (N=201) showed that semaglutide 2.4 mg reduced BMI by 16.1% versus a 0.6% increase with placebo at 68 weeks in this population [19].

Certain patients should not take GLP-1 RAs. These medications carry a boxed warning about thyroid C-cell tumors based on rodent studies, and they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) [20]. They should not be used during pregnancy. Patients with a history of pancreatitis require careful evaluation before starting therapy.

A thorough medical assessment before prescribing is standard. This typically includes baseline labs (metabolic panel, HbA1c, lipid panel, thyroid function), review of current medications for interactions, and screening for contraindications. Patients already taking insulin or sulfonylureas may need dose adjustments to avoid hypoglycemia.

What to Expect: Timeline, Side Effects, and Dose Escalation

GLP-1 RA treatment follows a gradual dose escalation schedule designed to minimize gastrointestinal side effects. Semaglutide (Wegovy) starts at 0.25 mg weekly for 4 weeks, then increases through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg at approximately week 16 [10]. Tirzepatide (Zepbound) follows a similar pattern, beginning at 2.5 mg weekly and escalating every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and potentially 15 mg [11].

The most common side effects are gastrointestinal. In STEP 1, nausea occurred in 44% of semaglutide patients versus 18% with placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11% [10]. These events were predominantly mild to moderate in severity. Most nausea peaked during dose escalation and subsided within 4 to 8 weeks at each new dose level. Only 7% of participants discontinued semaglutide due to adverse events.

Tirzepatide shows a similar gastrointestinal profile. In SURMOUNT-1, nausea affected 24% to 33% of participants across dose groups (compared to 9.5% placebo), and discontinuation rates from adverse events ranged from 4.3% to 7.1% [11].

Rare but serious adverse events include pancreatitis (reported in fewer than 0.5% of patients across trials), gallbladder-related events such as cholelithiasis (approximately 1.5% to 2.5% in semaglutide trials), and, very rarely, intestinal obstruction [20]. The FDA also issued guidance in 2023 noting reports of ileus in some patients, though a causal relationship remains unconfirmed.

Practical tips for managing side effects include eating smaller, more frequent meals, avoiding high-fat or greasy foods (especially during escalation), staying well-hydrated, and not lying down immediately after eating.

Why Weight Regain Happens After Stopping

GLP-1 medications treat obesity as a chronic condition, not a short course of therapy. The STEP 1 extension study demonstrated that after 68 weeks on semaglutide, participants who switched to placebo regained approximately two-thirds of their lost weight within one year [21]. This finding is not a flaw in the medication. It reflects the underlying biology of obesity, in which the body's weight-regulation system actively works to restore prior body weight through increased hunger hormones, decreased energy expenditure, and neuroadaptive changes.

The 2022 American Gastroenterological Association (AGA) clinical practice guideline on pharmacological interventions for obesity states: "Obesity is a chronic, relapsing disease that requires long-term treatment. Medications should be continued as long as the patient derives benefit and does not experience unacceptable side effects" [22].

This does not mean patients must stay on the same dose indefinitely. Some clinicians explore maintenance at lower doses once target weight is achieved. Preliminary data from the STEP 4 trial suggest that ongoing treatment, even at the full dose, is needed to maintain maximum weight reduction [23]. Research into optimal long-term dosing strategies continues.

GLP-1 Medications Compared to Older Weight Loss Drugs

Prior to GLP-1 RAs, the available anti-obesity pharmacotherapy produced modest results. Phentermine-topiramate (Qsymia) achieved approximately 9.8% weight loss at one year in the CONQUER trial [24]. Naltrexone-bupropion (Contrave) produced roughly 5% to 6% weight loss at 56 weeks in the COR trials [25]. Orlistat (Xenical, Alli) yielded about 3% weight loss beyond placebo.

The gap between these older medications and GLP-1 RAs is significant. Semaglutide's 14.9% mean weight loss and tirzepatide's 22.5% represent a two- to four-fold improvement over the previous best medical options. For comparison, Roux-en-Y gastric bypass typically produces 25% to 30% total body weight loss at 2 years [26]. Tirzepatide's results are now within range of surgical outcomes for many patients.

This does not mean GLP-1 RAs replace surgery for everyone. Bariatric surgery remains the most effective intervention for patients with severe obesity (BMI of 40 or greater) and offers benefits including type 2 diabetes remission rates exceeding 60% at 5 years. The 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity (IFSO) joint guidelines lowered the BMI threshold for considering surgery to 35 without comorbidities and 30 with metabolic disease [27]. GLP-1 RAs provide a non-surgical alternative or a bridge to surgery for patients who are not candidates or who prefer pharmacotherapy.

Cost, Insurance Coverage, and Access Barriers

The list price of GLP-1 medications for weight loss remains a significant barrier. Wegovy carries a list price of approximately $1,349 per month, and Zepbound is priced at roughly $1,060 per month without insurance [28]. Coverage varies widely by health plan. Medicare Part D currently does not cover anti-obesity medications, though bipartisan legislation (the Treat and Reduce Obesity Act) has been reintroduced in Congress multiple times to change this.

Commercial insurance coverage has expanded since 2023. Large employers and several state Medicaid programs now include GLP-1 RAs for weight management, often with prior authorization requirements. Novo Nordisk and Eli Lilly both offer patient savings programs that may reduce out-of-pocket costs for eligible commercially insured patients.

The supply chain has also presented challenges. Wegovy and Zepbound experienced intermittent shortages in 2024 and early 2025 due to manufacturing constraints paired with unprecedented demand. The FDA maintained both medications on its drug shortage list through portions of this period [29]. Patients starting treatment should confirm product availability with their pharmacy before beginning dose escalation to avoid gaps in therapy.